AtriCure Q2 Adj EPS $(0.12) Beats $(0.29) Estimate, Sales $100.92M Beat $97.49M Estimate
Portfolio Pulse from vinayak@benzinga.com
AtriCure (NASDAQ:ATRC) reported Q2 adjusted EPS of $(0.12), beating the estimate of $(0.29) by 58.62%. The company also reported quarterly sales of $100.92M, surpassing the estimate of $97.49M by 3.52%. This represents a 62.5% increase in EPS and a 19.39% increase in sales compared to the same period last year.
July 25, 2023 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AtriCure's Q2 results exceeded estimates, with a significant increase in EPS and sales compared to last year. This could potentially boost investor confidence.
AtriCure's better-than-expected Q2 results, including a significant increase in EPS and sales compared to the same period last year, could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100